113 related articles for article (PubMed ID: 21452120)
21. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
22. Infectious complications of biologic agents.
Martin-Mola E; Balsa A
Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
[TBL] [Abstract][Full Text] [Related]
23. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
24. Progressive multifocal leukoencephalopathy: what's new?
Focosi D; Marco T; Kast RE; Maggi F; Ceccherini-Nelli L; Petrini M
Neuroscientist; 2010 Jun; 16(3):308-23. PubMed ID: 20479473
[TBL] [Abstract][Full Text] [Related]
25. Testing human biologicals in animal host resistance models.
Burleson GR; Burleson FG
J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
[TBL] [Abstract][Full Text] [Related]
26. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
27. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
28. Infectious complications of biological therapy.
Haroon N; Inman RD
Curr Opin Rheumatol; 2009 Jul; 21(4):397-403. PubMed ID: 19412102
[TBL] [Abstract][Full Text] [Related]
29. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
Weisman MH
J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
[TBL] [Abstract][Full Text] [Related]
30. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
31. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
32. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents?
Renoult E; Buteau C; Lamarre V; Turgeon N; Tapiero B
Pediatr Transplant; 2005 Aug; 9(4):470-9. PubMed ID: 16048599
[TBL] [Abstract][Full Text] [Related]
33. Overview of infection with the human immunodeficiency virus: infectious complications.
Gold JW
Clin Chest Med; 1988 Sep; 9(3):377-86. PubMed ID: 2842109
[TBL] [Abstract][Full Text] [Related]
34. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
Stüve O; Wiendl H
Neurology; 2009 Oct; 73(17):1346-7. PubMed ID: 19776376
[No Abstract] [Full Text] [Related]
35. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
36. [Toxoplasmosis and immunosuppression].
Djurković-Djaković O
Srp Arh Celok Lek; 1998; 126(5-6):197-203. PubMed ID: 9863381
[TBL] [Abstract][Full Text] [Related]
37. [Biologics and infections in rheumatic diseases].
Hügle T; Daikeler T; Tyndall A
Ther Umsch; 2014 Jan; 71(1):45-53. PubMed ID: 24394208
[TBL] [Abstract][Full Text] [Related]
38. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
39. "Thinking without thinking" about natalizumab and PML.
Ransohoff RM
J Neurol Sci; 2007 Aug; 259(1-2):50-2. PubMed ID: 17521672
[TBL] [Abstract][Full Text] [Related]
40. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis.
Fessler BJ
Best Pract Res Clin Rheumatol; 2002 Apr; 16(2):281-91. PubMed ID: 12041954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
